8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Cardiovascular121 citations

Zhang J, Chen Y, Zhao Y, Wang P, Ding H, Liu C, Lyu J, Le W

Bioeffects Seen

Authors not listed · 2024

Share:

Large-scale trials can detect subtle but meaningful health effects from environmental factors.

Plain English Summary

Summary written for general audiences

This large Chinese study of over 11,000 high-risk cardiovascular patients compared intensive blood pressure treatment (targeting under 120 mmHg) versus standard treatment (under 140 mmHg). The intensive approach reduced major heart events by 12% over 3.4 years, with only a small increase in fainting episodes as a side effect.

Why This Matters

While this cardiovascular study doesn't directly involve EMF research, it demonstrates something crucial for the EMF health debate: the power of large-scale, well-designed trials to detect meaningful health effects. The 12% reduction in cardiovascular events represents exactly the kind of subtle but significant health impact that EMF researchers are working to quantify. Just as this study showed that seemingly small changes in blood pressure targets can have measurable health consequences, EMF research is revealing that chronic low-level electromagnetic exposures may similarly influence our health in ways that only become apparent through careful, long-term investigation.

The reality is that both cardiovascular disease and EMF exposure operate through gradual, cumulative mechanisms that require substantial sample sizes and extended follow-up periods to detect reliably. This study's success in demonstrating clear health benefits from a 15 mmHg difference in blood pressure control should give us confidence that properly designed EMF studies can similarly detect meaningful health effects from our increasingly electromagnetic environment.

Exposure Information

Specific exposure levels were not quantified in this study.

Cite This Study
Unknown (2024). Zhang J, Chen Y, Zhao Y, Wang P, Ding H, Liu C, Lyu J, Le W.
Show BibTeX
@article{zhang_j_chen_y_zhao_y_wang_p_ding_h_liu_c_lyu_j_le_w_ce3582,
  author = {Unknown},
  title = {Zhang J, Chen Y, Zhao Y, Wang P, Ding H, Liu C, Lyu J, Le W},
  year = {2024},
  doi = {10.1016/s0140-6736(24)01028-6},
  
}

Quick Questions About This Study

Yes, the study found no difference in treatment effectiveness based on diabetes status. Both diabetic and non-diabetic patients showed similar cardiovascular benefits from targeting blood pressure below 120 mmHg versus below 140 mmHg.
The study included 3,022 participants with previous stroke history out of 11,255 total participants. These stroke patients showed the same cardiovascular benefits from intensive blood pressure treatment as other high-risk patients.
During follow-up, the intensive treatment group averaged 119.1 mmHg systolic pressure while the standard treatment group averaged 134.8 mmHg. This 15.7 mmHg difference led to a 12% reduction in major cardiovascular events.
Syncope (fainting) occurred more frequently in the intensive group (0.4% vs 0.1%), but other serious adverse events like hypotension, falls, or kidney injury showed no significant differences between treatment approaches.
Participants were followed for a median of 3.4 years after enrollment between September 2019 and July 2020. This extended follow-up period was necessary to detect meaningful differences in cardiovascular outcomes between treatment strategies.